Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Evaluation of uricosuric agents in chronic gout.

Literature DB >> 13498593

Evaluation of uricosuric agents in chronic gout.

M A OGRYZLO, J HARRISON.

Abstract

Entities: Disease

Keywords: GOUT/therapy

Mesh：

Substances：
Uricosuric Agents

Year: 1957 PMID： 13498593 PMCID： PMC1006984 DOI： 10.1136/ard.16.4.425

Source DB: PubMed Journal: Ann Rheum Dis ISSN： 0003-4967 Impact factor: 19.103

× No keyword cloud information.

23 in total

1. The uricosuric action of ethyl biscoumacetate.

Authors: R SOUGIN-MIBASHAN; M HORWITZ
Journal: Lancet Date: 1955-06-11 Impact factor: 79.321

2. A potent new uricosuric agent, the sulfoxide metabolite of the phenylbutazone analogue, G-25671.

Authors: J J BURNS; T F YU; A RITTERBAND; J M PEREL; A B GUTMAN; B B BRODIE
Journal: J Pharmacol Exp Ther Date: 1957-03 Impact factor: 4.030

3. Management of gout.

Authors: W BAUER; M M SINGH
Journal: N Engl J Med Date: 1957-01-31 Impact factor: 91.245

4. The effect of phenylbutazone on uric acid metabolism in two normal subjects.

Authors: J B WYNGAARDEN
Journal: J Clin Invest Date: 1955-02 Impact factor: 14.808

5. Probenecid (benemid); its uses and side-effects in 2,502 patients.

Authors: W P BOGER; S C STRICKLAND
Journal: AMA Arch Intern Med Date: 1955-01

6. Further observation on the uricosuric effects of probenecid (benemid) in tophaceous gout.

Authors: A B GUTMAN; T F YU; V RANDOLPH
Journal: Trans Assoc Am Physicians Date: 1954

7. Effect of phenylbutazone on uric acid excretion in patients with gout and rheumatoid arthritis.

Authors: C BISHOP; L BEECHER
Journal: Proc Soc Exp Biol Med Date: 1953-07

8. The clinical and metabolic effects of benemid in patients with gout.

Authors: J H TALBOTT; C BISHOP; B M NORCROSS; L M LOCKIE
Journal: Trans Assoc Am Physicians Date: 1951

9. URIC acid metabolism and gout.

Authors:
Journal: Am J Med Date: 1950-12 Impact factor: 4.965

10. Observations on the antirheumatic and physiologic effects of phenylbutazone (butazolidin) and some comparisons with cortisone.

Authors: B B BRODIE; E W LOWMAN; J J BURNS; P R LEE; T CHENKIN; A GOLDMAN; M WEINER; J M STEELE
Journal: Am J Med Date: 1954-02 Impact factor: 4.965

10 in total

1. Study of the paradoxical effects of salicylate in low, intermediate and high dosage on the renal mechanisms for excretion of urate in man.

Authors: T F YU; A B GUTMAN
Journal: J Clin Invest Date: 1959-08 Impact factor: 14.808

2. MUTUAL SUPPRESSION OF THE URICOSURIC EFFECTS OF SULFINPYRAZONE AND SALICYLATE: A STUDY IN INTERACTIONS BETWEEN DRUGS.

Authors: T F YUE; P G DAYTON; A B GUTMAN
Journal: J Clin Invest Date: 1963-08 Impact factor: 14.808

3. Sulphinpyrazone in the treatment of arthritis associated with hyperuricaemia.

Authors: E N GLICK
Journal: Proc R Soc Med Date: 1961-05

4. Value of uricosuric agents and in particular of G. 28 315 in gout.

Authors: G D KERSLEY; E R COOK; D C TOVEY
Journal: Ann Rheum Dis Date: 1958-09 Impact factor: 19.103

5. Phenylbutazone and its derivatives with special reference to G.27202.

Authors: F D HART; D BURLEY
Journal: Br Med J Date: 1959-04-25

6. NEW DRUGS.

Authors:
Journal: Can Med Assoc J Date: 1959-04-01 Impact factor: 8.262

7. Population pharmacokinetics and exposure-uric acid analyses after single and multiple doses of ABT-639, a calcium channel blocker, in healthy volunteers.

Authors: Guohua An; Wei Liu; W Rachel Duan; Wolfram Nothaft; Walid Awni; Sandeep Dutta
Journal: AAPS J Date: 2015-01-08 Impact factor: 4.009